A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

The stock's fall snapped a two-day winning streak.

The already crowded field of biomarker-targeted drugs is poised to only get busier with new biomarkers, ADCs, and cancer vaccines.

Hyderabad: The queue of global pharma giants wanting to make Hyderabad their new home for drug discovery and tech centres is ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organisations is failing to protect ...

Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and ...

The ETF comes with an expense ratio of 0.55% and mirrors the Alger Russell Innovation Index, which focuses on innovative ...

New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

Bristol Myers Squibb is doubling down on a partnership with Medidata, signing a multiyear agreement to continue using the ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

Highlights,Bristol-Myers Squibb beats quarterly earnings estimates.,Dividend increased, maintaining strong returns.,Insider ...

The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...